Secretome for Facial Aging
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment for facial rejuvenation using secretome, derived from an individual's own hair follicles. It compares the effects of secretome against a placebo (a harmless substance with no therapeutic effect) to assess its ability to improve signs of facial aging, such as wrinkles and skin roughness. Individuals with moderate to very severe facial aging who are willing to avoid other cosmetic procedures during the study might be suitable candidates. As an Early Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative treatment.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but certain medications like isotretinoin, immunosuppressants, and anticoagulants are not allowed. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that the Autologous Hair Follicle-Derived Secretome treatment is likely to be safe for humans?
Research has shown that using secretions from an individual's own hair follicles for skin treatments has been studied for safety. Previous studies suggest this method could effectively rejuvenate the skin. Since the secretions originate from the individual's body, they may offer a safer option.
Another study examined secretions from fat tissue and found them safe for skin treatments. Although this involves a different source, it suggests that using secretions, in general, can be safe, supporting the safety of hair follicle secretions.
This trial is in its early stages, with the treatment still undergoing safety testing in people. Early trials typically involve small groups to identify any serious side effects. While the treatment appears promising, further research is necessary to fully understand its safety.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for facial aging, which often include topical retinoids, fillers, or botulinum toxin injections, the autologous hair follicle-derived secretome uses a unique approach. This treatment leverages the secretome, a collection of proteins and growth factors naturally produced by hair follicles, to rejuvenate the skin. Researchers are excited because this method could stimulate the skin's own repair processes, potentially offering a more natural and holistic anti-aging effect. Additionally, since the secretome is derived from the individual's own cells, it may reduce the risk of adverse reactions compared to synthetic treatments.
What evidence suggests that this treatment might be an effective treatment for facial aging?
Research suggests that substances from one's own hair follicles might refresh and improve facial appearance. In this trial, participants will receive either the Autologous Hair Follicle-Derived Secretome or a placebo control. This treatment uses natural secretions from hair follicles to enhance skin appearance. Similar methods have shown promise in studies for improving skin issues like acne scars and wrinkles. For example, secretions from fat tissue have effectively lightened skin and made it more youthful, with noticeable improvements in sun spots and wrinkles. These secretions are believed to harness the healing abilities of cells without needing to transplant the cells themselves. While the results are promising, further research is needed to confirm effectiveness specifically for facial aging.15678
Are You a Good Fit for This Trial?
This trial is for men and women aged 30-70 with moderate to severe facial aging who are willing to avoid other cosmetic procedures, new skin care products, and minimize sun exposure. They must not have had recent surgery or certain treatments, be on specific medications like isotretinoin or immunosuppressants, have autoimmune conditions, a history of cancer treatment within 5 years, or plan pregnancy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intradermal injections of the secretome or placebo for facial rejuvenation
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Control patients may opt to cross-over and receive active treatment
What Are the Treatments Tested in This Trial?
Interventions
- Autologous Hair Follicle-Derived Secretome
Find a Clinic Near You
Who Is Running the Clinical Trial?
Acorn Biolabs Inc.
Lead Sponsor